Cancer cells exhibit a heightened reliance on de novo lipogenesis, even in the presence of abundant extracellular lipids, with key enzymes such as ACLY, ACC1, and FASN identified as promising therapeutic targets [34–36]. The gene discussed is FASN; the disease is cancer.